Press release content from ACCESSWIRE. The AP news staff was not involved in its creation.
Click to copy
CARLSBAD, CA / ACCESSWIRE / November 15, 2019 / International Stem Cell Corporation (OTCQB:ISCO) ( http://www.internationalstemcell.com ) (ISCO or the Company), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today announced operating results for the three and nine months ended September 30, 2019.
As we mentioned before we completed the enrollment of the Phase I Parkinsons disease clinical trial and currently involved in reorganizing our revenue-generating subsidiaries. We expect that we will see positive results of this reorganization next year. - commented Andrey Semechkin, PhD., CEO and Co-Chairman of ISCO.
Year-to-Date Financial Highlights
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCOs core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology ( http://www.lifelinecelltech.com ), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at http://www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: http://www.facebook.com/InternationalStemCellCorporation and http://www.twitter.com/intlstemcell
Safe Harbor Statement
Statements pertaining to anticipated developments, expected results of clinical studies, progress of research and development, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as will, believes, plans, anticipates, expects, estimates,) should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the companys business, particularly those mentioned in the cautionary statements found in the companys Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
International Stem Cell Corporation and Subsidiaries Condensed Consolidated Balance Sheets (in thousands, except share data and par value) (Unaudited)
Assets
Cash
Accounts receivable, net
Inventory, net
Prepaid expenses and other current assets
Total current assets
Non-current inventory
Property and equipment, net
Intangible assets, net
Right-of-use assets
Deposits and other assets
Total assets
Liabilities, Redeemable Convertible Preferred Stock, and Stockholders' Equity (Deficit)
Accounts payable
Accrued liabilities
Operating lease liabilities, current
Related party payable
Advances
Warrant liability
Total current liabilities
Long-term deferred rent
Operating lease liabilities, net of current portion
Total liabilities
Commitments and Contingencies
Series D Redeemable Convertible Preferred stock, $0.001 par value, 50 shares authorized, 43 issued and
outstanding, with liquidation preference of $4,300 at September 30, 2019
Stockholders' Equity (Deficit)
Series B Convertible Preferred stock, $0.001 par value, 5,000,000 shares authorized, 250,000
issued and outstanding, with liquidation preferences of $423 and $411 at September 30, 2019 and
December 31, 2018
Series D Convertible Preferred stock, $0.001 par value, 50 shares authorized, 43 issued and
outstanding, with liquidation preference of $4,300 at December 31, 2018
Series G Convertible Preferred stock, $0.001 par value, 5,000,000 shares authorized, issued and
outstanding, with liquidation preference of $5,000 at September 30, 2019 and December 31, 2018
Series I-1 Convertible Preferred stock, $0.001 par value, 2,000 shares authorized, 814 issued and
outstanding, with liquidation preferences of $814 at September 30, 2019 and December 31, 2018
Series I-2 Convertible Preferred stock, $0.001 par value, 4,310 shares authorized,
issued and outstanding with liquidation preference of $4,310 at September 30, 2019 and December 31, 2018
Common stock, $0.001 par value, 120,000,000 shares authorized, 7,533,083 and 6,933,861 shares
issued and outstanding at September 30, 2019 and December 31, 2018
Additional paid-in capital
Accumulated deficit
Total stockholders' equity (deficit)
Total liabilities, redeemable convertible preferred stock and stockholders' equity (deficit)
International Stem Cell Corporation and Subsidiaries Condensed Consolidated Statements of Operations (in thousands, except per share data) (Unaudited)
Revenues
Product sales
Total revenues
Expenses
Cost of sales
Research and development
Selling and marketing
General and administrative
Total expenses
Loss from operations
Other income (expense)
Change in fair value of warrant liability
Interest expense
Miscellaneous income
Total other income (expense), net
Net income (loss)
Net income (loss) applicable to common stockholders
Net income (loss) per common share-basic
Net income (loss) per common share-diluted
Weighted average shares-basic
Weighted average shares-diluted
Contacts:
International Stem Cell Corporation
Russell A. Kern, PhD
Phone: 760-940-6383
Email:
SOURCE: International Stem Cell CORP
View source version on accesswire.com:
Read more here:
International Stem Cell Corporation Announces Financial Results for the Three and Nine-Months ended September 30, 2019 - Associated Press
- Stem Cell Science and Human Research Studies Ahead of Cargo Arrival - NASA Blogs - February 21st, 2024
- Harvard Stem Cell Institute (HSCI) - December 29th, 2023
- Stem cell - Wikipedia - December 29th, 2023
- A Look Inside Stem Cells Helps Create Personalized Regenerative ... - May 17th, 2023
- Heart disease study shows hope for stem cell treatment - March 4th, 2023
- Focus On Stem Cell Research | National Institute of Neurological ... - March 4th, 2023
- Stem Cell Research: Argumentative Essay - Free Essay Example - Edubirdie - March 4th, 2023
- Automated Cell Culture Systems Market Size to Hit USD 12.43 Billion by 2033; Growing Stem Cell Research & Development and Increasing Prevalence of... - October 21st, 2022
- NIH Guidelines for Human Stem Cell Research - October 13th, 2022
- Ethics of Stem Cell Research - Blue Marble Space Institute of Science - October 13th, 2022
- Global Cell Therapy Market Report (2022 to 2028) - Featuring Thermo Fisher Scientific, MaxCyte, Danaher and Avantor Among Others -... - October 13th, 2022
- Stem Cell Therapy Market (2022-2029) Size Will Escalate Rapidly in the Near Future: Osiris Therapeutics, Molmed - Digital Journal - October 13th, 2022
- Fighting One Disease or Condition per Day - Daily Kos - October 13th, 2022
- The Issue of Tissue: Getting to the Source of the HIV Reservoir - amfAR, The Foundation for AIDS Research - October 13th, 2022
- Cell Isolation Global Market Report 2022: Significant Growth in the Medical and Pharmaceutical Industries Driving Sector - ResearchAndMarkets.com -... - October 13th, 2022
- Nancy and Geoffrey Stack Family Foundation give $2 million to UCI Health - UCI News - October 4th, 2022
- Cell Isolation Market is expected to generate a revenue of USD 20.50 Billion by 2028, Globally, at 15.70% CAGR: Verified Market Research -... - September 25th, 2022
- Creating stem cells from minipigs offers promise for improved treatments - University of Wisconsin-Madison - September 16th, 2022
- Hemostemix Announces the Appointment of Dr. Renzo Cecere, MD, FRCSC to Its Scientific Advisory Board - Yahoo Finance - September 16th, 2022
- Genomics study identifies unique set of proteins that restores hearing in zebrafish - National Institutes of Health (.gov) - September 16th, 2022
- Discovered Key Mechanisms to Improve Intestinal Regeneration and Alleviate the Side Effects of Radiotherapy - Imaging Technology News - September 16th, 2022
- Global Cell Expansion Market Size to Grow at a CAGR of 15% during the Forecast Period 2022-2027 - Digital Journal - September 16th, 2022
- The American Cancer Society Awards $2.1 Million to Montefiore Einstein Cancer Center to Support Cancer Research and Tackle Inequities - Yahoo Finance - September 16th, 2022
- Hair Restoration Market | Stem Cell hair Restoration and Low-level Laser Therapy (LLLT) segment are Expected to Witness Significant CAGR - MDC... - August 30th, 2022
- Stem Cell Therapy for Parkinson's: Current Developments - Healthline - August 5th, 2022
- 'Off the shelf' CAR T cells for cancer treatment? - Boston Children's Answers - Boston Children's Discoveries - August 5th, 2022
- Inflammation accelerates aging of the hematopoietic system - EurekAlert - August 5th, 2022
- New patent-pending method mass-produces antitumor cells to treat blood diseases and cancer - Purdue University - August 5th, 2022
- Cell Therapy Technologies Market worth $8.0 billion by 2027 - Exclusive Report by MarketsandMarkets - PR Newswire - August 5th, 2022
- Twenty-Five Years After My House Call To Dolly: What Have We Learned About Cloning And How Did We Learn It? - Forbes - August 5th, 2022
- Tendon Stem Cell Therapy Market is Booming Worldwide with Strong Growth Prospects | Cellualar Dynamics, Cellectis, International Stem cell... - July 27th, 2022
- [Pangyo Bio & Medical] Theragen Bio discovers MAST4 Protein that Regulates Bone Cartilage Development For 'The First Time in The World' - Digital... - July 27th, 2022
- Cell Culture Media Market Size Worth $10.2 Billion by 2030: Grand View Research, Inc. - PR Newswire - July 27th, 2022
- Cryopreservation Equipment Market Report 2022-2028: Importance of Cryopreservation for Success of Cell-Based Therapies Presents Opportunities -... - July 27th, 2022
- Whitmer axes stem cell research, pregnancy center funding over abortion access concerns - MLive.com - July 19th, 2022
- Stem Cell - National Human Genome Research Institute Home - July 11th, 2022
- Induced Pluripotent Stem Cells (iPS) | UCLA Broad Stem Cell Center - July 11th, 2022
- Global 3D Cell Culture Market To Be Driven By Growing Impact Of Economy On Regenerative Medicine, Emerging Applications Of Gene Therapy During The... - July 11th, 2022
- New Combination Therapy Effective in Pediatric Leukemia - Technology Networks - June 22nd, 2022
- MIT Pioneers Technology To Grow Customizable Wood Products in the Lab With Little Waste - SciTechDaily - June 22nd, 2022
- First-of-its-Kind Stem Cell and Gene Therapy Highlighted at Annual Stem Cell Meeting - Newswise - June 13th, 2022
- Scientists hope this injectable stem cell gel can repair heart attack damage and avoid transplants - Euronews - June 13th, 2022
- Axol Bioscience Introduces CiPA-Validated Human Stem Cell-Derived Ventricular Cardiomyocytes to Help Improve Drug Discovery - Business Wire - June 13th, 2022
- Fasting has pros and cons for muscle repair in mice - Futurity: Research News - June 13th, 2022
- First Clinical Trial of Transplanted 3D Ear Using Human Cells Proves Successful via 3DBio Therapeutics - Tech Times - June 4th, 2022
- Insights on the Dimethyl Sulfoxide (DMSO) Global Market to 2027 - Expanding Research and Development in Stem Cell Transplantation to Benefit Demand... - May 15th, 2022
- Scientists Rejuvenate Skin Cells by 30 Years, with Pioneering Potential - BioSpace - May 15th, 2022
- Global Flow Cytometry Market is expected to grow at a lucrative rate of 8% to reach $11 billion by 2026 A Robust Tool that Defines New Era for... - May 15th, 2022
- Global Mesenchymal Stem Cells Market Research Report to 2027 - Featuring Astellas Pharma, Axol Biosciences and BrainStorm Cell Therapeutics Among... - May 2nd, 2022
- Researchers share insights about the mechanisms of human embryo and create method to develop transcriptionally similar cells in tissue culture -... - May 2nd, 2022
- Flow Cytometry Market is Estimated Drive the Industry Growth Across World in Coming Year 2030 Queen Anne and Mangolia News - Queen Anne and Mangolia... - May 2nd, 2022
- Mini-heart chamber beats on its own just like the real thing - Futurity: Research News - May 2nd, 2022
- The Case Against Embryonic Stem Cell Research: An ... - April 6th, 2022
- Burst of accumulated zinc shows how the mineral boosts immune function, suggesting ways to improve health - EurekAlert - April 6th, 2022
- Hoyer Statement on the Retirement of Congressman Fred Upton - Majority Leader - April 6th, 2022
- 11 Stem Cell Research Pros and Cons Vittana.org - March 25th, 2022
- Research Associate, Cancer and Stem Cell Laboratory job with UNIVERSITY OF SYDNEY | 287031 - Times Higher Education - March 25th, 2022
- Google still has a problem with stem cell and unproven therapies - STAT - STAT - March 25th, 2022
- Medeze Named Frost & Sullivan's 2021 Company of the Year in the Southeast Asia Stem Cell Banking Industry - PR Newswire - March 25th, 2022
- Bone Marrow-Derived Stem Cells (BMSCS) Market Report- Growth in Future with Size, Share, Growth, and Key Companies Analysis Cord Blood Registry... - March 25th, 2022
- Autologous Stem Cell and Non-Stem Cell Based Therapies Market Future Business Opportunities 2022-2028 | Caladrius Biosciences, Vericel Corporation,... - March 25th, 2022
- Cell Therapy Market Trends, Revenue, Key Players, Growth, Share and Forecast Till 2028 Reports and Data - Digital Journal - March 25th, 2022
- This Fancy AF Face Cream Was Invented by a Stem Cell Researcher - VICE - March 25th, 2022
- Freeze Thaw Chambers Market: The cryopreserved products segment is expected to drive the growth of the market - BioSpace - January 5th, 2022
- As Nave as They Get - Weizmann Wonder Wander - News, Features and Discoveries - Weizmann Institute of Science - January 5th, 2022
- Jake's mice: Searching for answers to the puzzle of autism - huntingdondailynews.com - January 5th, 2022
- Primary Cells, Stem Cells, Culture Media and Reagents Market to Witness Rapid Growth by 2029 | BrainStorm Cell Therapeutics Inc., Caladrius... - January 5th, 2022
- Gait Rehabilitation System Market: Rising incidence of various neurological disorders to drive the market - BioSpace - January 5th, 2022
- ARVO Foundation Announces 2022 Bert M. Glaser, MD Award for Innovative Retina Research Recipient - Newswise - January 5th, 2022
- Communication between cells plays a major role in deciding their fate - EurekAlert - December 24th, 2021
- The 10 Most Compelling Research Stories of 2021 - BioSpace - December 24th, 2021
- MRC Lead Apologizes Following Bullying Allegations - The Scientist - December 24th, 2021
- California Proposition 14, Stem Cell Research Institute ... - November 22nd, 2021
- Ethical Issues in Stem Cell Research - PubMed Central (PMC) - November 22nd, 2021
- Opinion | How Covid Raised the Stakes of the War Between Faith and Science - The New York Times - November 8th, 2021
- What is Stem Cell Research? | The Benefits of Stem Cell Research - October 5th, 2021
- An Overview of Stem Cell Research | The Center for Bioethics ... - October 5th, 2021
- Stem Cell Research: Uses, Types & Examples - October 5th, 2021
- Stem Cells | National Institutes of Health (NIH) - October 5th, 2021
- Stem cells: Therapy, controversy, and research - October 5th, 2021